Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Walgreens Boots Alliance Inc (NASDAQ: WBA) are up 2.0% in premarket trading after the company reported market-beating results for its fiscal fourth quarter on Thursday. Walgreens' financial performance in the fourth quarter Walgreens reported $627 million in net income that translates to 72 cents per share.

Walgreens CEO: vaccine mandates helped boost results in Q4

Walgreens (WBA) delivered earnings and revenue surprises of 13.59% and 2.96%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Tops Q4 Earnings and Revenue Estimates

Kinnevik AB (publ) ("Kinnevik”) today announced its support of the Walgreens Boots Alliance (“WBA”) announcement to invest an additional USD 5.2bn in VillageMD to expand their partnership. As part of this transformational transaction, Kinnevik has committed to sell a minimum USD 340m interest in VillageMD to WBA. After the transaction, Kinnevik expects to retain an approximate 4 percent stake in VillageMD.

VillageMD and Walgreens Enter Into Transformational Transaction in Which Kinnevik Has Committed to Sell a Minimum USD 340 Million Interest in VillageMD

The drugstore chain wants to turn its neighborhood drugstores into more of a health-care destination.

Walgreens boosts stake in primary care company VillageMD with a $5.2 billion investment

DEERFIELD, Ill. & CHICAGO--(BUSINESS WIRE)---- $WBA--WBA and VillageMD announced that WBA has agreed to make an additional investment in VillageMD to advance its delivery of value-based primary care.

Walgreens Boots Alliance Makes $5.2 Billion Investment in VillageMD to Deliver Value-Based Primary Care to Communities Across America

Walgreens will invest $5.2 billion in VillageMD to open at least 600 Village Medical at Walgreens primary care practices in more than 30 U.S. markets by 2025.

Walgreens Takes Bigger $5.2 Billion Stake In Doctor Clinic Partner VillageMD

Retail pharmacy chain Walgreens Boots Alliance Inc (NASDAQ: WBA) reported fourth-quarter FY21 sales growth of 12.8% year-over-year to $34.26 billion, and an 11.8% increase on a constant currency basis, beating the consensus of $33.3 billion. Adjusted EPS improved by 29.5% Y/Y to $1.17, beating the consensus of $1.02.

Walgreens Boots Alliance Q4 Earnings Beat Estimates

Walgreens reported adjusted earnings for its fiscal fourth quarter of $1.17, beating the FactSet consensus estimate of $1.02 per share.

Walgreens Stock Gains as Earnings Top Estimates. Credit Covid.

Walgreens Boots Alliance Inc. WBA, -0.34% shares rose 2.5% in Thursday premarket trading after the pharmacy retailer reported fiscal fourth-quarter earnings and sales that beat expectations. Net income totaled $627 million, or 72 cents per share, up from $373 million, or 43 cents per share, last year.

Walgreens profit and sales beat expectations

Walgreens Boots Alliance Inc reported a 68% surge in fourth-quarter profit on Thursday, as it benefited from higher sales at its pharmacy stores in the United States and the United Kingdom.

Walgreens profit surges 68% on strong pharmacy, retail sales

The drugstore chain will hold an investor day and lay out its growth plans on Thursday.

Walgreens earnings top estimates, as drugstore gives twice as many Covid vaccines as expected

DEERFIELD, Ill.--(BUSINESS WIRE)---- $WBA #earnings--Walgreens Boots Alliance, Inc. today announced financial results for the fiscal year and fourth quarter that ended Aug. 31, 2021.

Walgreens Boots Alliance Reports Fiscal Year 2021 Earnings

Walgreens Boots Alliance Inc. has announced that it will close five Walgreens stores in San Francisco in response to the rise in organized retail crime.

Walgreens shutting five San Francisco locations due to organized retail crime

WBA is set to give its latest quarterly earnings report on Thursday, 2021-10-14. Here's what investors need to know before the announcement.

Walgreens Boots Alliance's Earnings: A Preview

After Walgreens locations in San Francisco struggled with shoplifting for years, the company opted to close five more of its Bay Area stores.

Walgreens plans to close 5 San Francisco stores, citing rampant shoplifting and 'organized retail crime'

Blue-chip name Walgreens Boots Alliance Inc (NASDAQ:WBA) just announced two major leadership appointments.

Blue-Chip Retailer Switches Up Leadership Ahead of Earnings

Taiwan Semiconductor Manufacturing

UnitedHealth Group

U.S. equity markets got off to a slow start this week with the S&P 500 and the Dow Jones industrials both closing essentially flat Monday and the Nasdaq up by about 0.2%.

Earnings Previews: Taiwan Semiconductor, United Healthcare, Walgreens

Walgreens Boots Alliance is scheduled to report its fiscal Q4 2021 results on Thursday, October 14. We expect the company to likely post revenue and earnings above the street expectations, primarily driven by post-pandemic recovery in all segments as well as Covid-19 vaccine administration.

What To Expect From Walgreens' Stock As It Reports Q4 Results?

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced two key executive leadership positions.

Walgreens Boots Alliance Announces Two Key Leadership Appointments

Apple

Salesforce

The world's most iconic stock index is harboring two amazing values, as well as one widely owned stock that's best avoided.

2 Dow Stocks to Buy Hand Over Fist and 1 to Avoid in the Fourth Quarter

Walgreens (WBA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Walgreens (WBA) Ahead of Earnings?

Walgreens (WBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Walgreens Boots Alliance (WBA) Expected to Beat Earnings Estimates: Should You Buy?

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance Marks Milestone, Reaches 300 Million Women and Children through Collaboration with Vitamin Angels

Walgreens Boots Alliance Marks Milestone, Reaches 300 Million Women and Children Through Collaboration with Vitamin Angels

Atmos Energy

Clorox

Federal Realty Investment Trust

PepsiCo

While the market rebounded smartly from the late September selling spree, where we finally reached a 5% decline after nearly a year without one, storm clouds are on the horizon once again.

5 Safe and Dependable Dividend Aristocrat Stocks are Perfect Q4 Buys Now

Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.

News for Walgreens Stock (WBA)